BIOMAT Database Logo BIOMAT Database Logo

Effects on host of modified PVP therapy combined with biological response modifiers in lung cancer. 1998

R Katoh, and S Takenoshita, and Y Shimizu, and S Tanaka, and Y Yajima, and Y Nagamachi
First Department of Surgery, Gunma University, School of Medicine, Japan.

We relieved several side effects by modifying chemotherapy and concurrently using biological response modifiers (BRMs) to experimentally and clinically investigate treatment, which can maintain quality of life (QOL) for lung cancer patients including changes in systemic immune capacity. sIL-2R levels are useful for predicting the course after recurrence. Immunosuppressive acid protein (IAP) levels are useful for detecting the presence or absence of recurrence and for predicting prognosis. BRMs are useful for continuing modified PVP (CDDP + VP-16) therapy, and sIL-2R and IAP levels for clarifying host conditions.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life

Related Publications

R Katoh, and S Takenoshita, and Y Shimizu, and S Tanaka, and Y Yajima, and Y Nagamachi
Biological response modifiers in cancer therapy.
January 2002, The National medical journal of India,
R Katoh, and S Takenoshita, and Y Shimizu, and S Tanaka, and Y Yajima, and Y Nagamachi
Cancer therapy by biological response modifiers.
January 1987, Clinical physiology and biochemistry,
R Katoh, and S Takenoshita, and Y Shimizu, and S Tanaka, and Y Yajima, and Y Nagamachi
Cancer therapy by biological response modifiers.
February 1987, Arzneimittel-Forschung,
R Katoh, and S Takenoshita, and Y Shimizu, and S Tanaka, and Y Yajima, and Y Nagamachi
Biological response modifiers in regional cancer therapy.
May 1991, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement,
R Katoh, and S Takenoshita, and Y Shimizu, and S Tanaka, and Y Yajima, and Y Nagamachi
Effects of biological response modifiers on lung natural killer activity.
January 1991, Immunopharmacology and immunotoxicology,
R Katoh, and S Takenoshita, and Y Shimizu, and S Tanaka, and Y Yajima, and Y Nagamachi
Therapy of peritoneal murine cancer with biological response modifiers.
January 1985, Journal of immunopharmacology,
R Katoh, and S Takenoshita, and Y Shimizu, and S Tanaka, and Y Yajima, and Y Nagamachi
[Radiotherapy combined with BRM (biological response modifiers) in the treatment of cancer].
August 1987, Gan no rinsho. Japan journal of cancer clinics,
R Katoh, and S Takenoshita, and Y Shimizu, and S Tanaka, and Y Yajima, and Y Nagamachi
Biological response modifiers for the therapy of cancer.
May 1985, Annals of allergy,
R Katoh, and S Takenoshita, and Y Shimizu, and S Tanaka, and Y Yajima, and Y Nagamachi
Approaches to cancer therapy using biological response modifiers.
May 1985, The Veterinary clinics of North America. Small animal practice,
R Katoh, and S Takenoshita, and Y Shimizu, and S Tanaka, and Y Yajima, and Y Nagamachi
Biological response modifiers in cancer.
November 2006, MedGenMed : Medscape general medicine,
Copied contents to your clipboard!